Connect with us

Biotechnology

Top Biotechnology Stocks To Watch This Quarter

Joe Samuel

Published

on

top biotechnology stocks to watch

One of the sectors that has consistently provided excellent potential over the years is the biotechnology sector. There are very few other industries that are as pivotal as this. New treatments and drug therapies are litterally life changing. In fact, as we’ve seen with many novel drugs when a new treatment hits the masses, it can have a dramatic impact on other industries as well.

However, an investor needs to do his research and keep an eye on the latest movements in order to stay ahead of the curve. Understanding what to look for when putting together a list of biotech stocks to watch is important. The FDA is a big catalyst for many drug companies.

So are things like phase trials that can be a proving ground for numerous would-be commercialized drugs. Here is a look at three biotech stocks that have made some interesting developments and could be on the radar for October.

PharmaCyte Biotech (PMCB)

If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

If you’re not familiar with this “IND,” the United States Food and Drug Administration’s Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines before a marketing application for the drug has been approved.

The company held a shareholder update call late last month to go over several key developments. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress.

PharmaCyte Biotech is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box®.

Axsome Therapeutics (AXSM)

One of the biotech stocks that skyrocketed this year was that of Axsome Therapeutics Inc (AXSM Stock Report ) but over the past two weeks the stock has given up as much as 42% of its gains. That being said, it is still up by as much as 490% this year.

There are some developments in the pipeline that could prove to be particularly beneficial to the stock price. The company’s lead candidate AXS-05 could be its ticket to the big time. It has created a special combination anti-depressant and if it is approved that it will be a whole new product in that particular space.

biotechnology stocks to watch AXSM

Additionally, the presence of bupropion in the product means that it could also be used as a medicine to quit smoking. At this point in time, the company has a market cap of $573 million but if AXS-05 proved to be successful then it could grow at an exponential rate in the next five years.

Kodiak Sciences (KOD)

The other biotech stock to watch closely is that of Kodiak Sciences Inc (KOD Stock Report ). The company is currently in the process of developing blindness preventing medicine that could corner a large portion of the market. Macular degeneration is caused due to old age and the new product by Kodiak is expected to be an improved version of all the medicines there are in the market at this point.

The product in question is KSI-301 and it is going to be much heavier dose than other products in the market. The company tested as many as 50 patients over a period of 12 weeks.

Results showed that it was on the same lines as another product that has already been awarded approval. The medicine could be worth billions in sales every year and investors should want the developments closely.

Continue Reading
Click to comment

Biotechnology

3 Penny Stocks Looking To Change The Biotech Industry

Jon Phillip

Published

on

biotechnology stocks

The world of biotech investing can be tricky. That’s particularly true when it comes to small-cap stocks in the industry. These companies often have terrific science, but no profits and little revenue; if any at all. But biotech stocks can offer true potential for investors who know what to look for.

Perhaps the best strategy for gaining exposure to this space is to look at early-stage, small-cap biotechs. By doing so, you put yourself at the front-line for cutting edge, experimental companies that could one day hit it big. Given this, here are 3 small-cap biotechs working to evolve in the biotech industry.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, INVESTORS & THE WORLD

GT Biopharma Inc. (GTBP)

One company making groundbreaking developments in the biotechnology field is GT Biopharma Inc. (GTBP). GT Biopharma Inc. is an immune-oncology biotech company determined to create new treatments for cancer. In order to do this, the company leverages its proprietary TriKE technology to develop its pipeline. As of now, GT Biopharma has 6 treatment plans undergoing the clinical trial process.

biotechnology stocks to buy now

So, what exactly is this TriKE technology platform? TriKE is actually an acronym for tri-specific killer engagers that are made to target NK’s or natural killer and tumor cells. Once they target NK cells, it binds to the CD16 receptor which makes a longer and stronger response compared to current treatment methods.

TriKE Therapy

One use of TriKE has been to develop a way to target the HIV-Env protein. The design to do this is known as HIV-TriKE. As a matter of fact, the company recently announced data that showed the effectiveness of HIV-TriKE. It was shown that it enhanced NK cell cytokine production and effectively killed infected targets with HIV-Env.

“We are pleased to see how the TriKE™ technology is able to be extended to the treatment of infectious disease and is able to kill HIV in the reservoir.”  Mr. Cataldo further stated, “We believe the HIV-TriKE™ will become part of a scalable and curative therapeutic strategy,” expressed Anthony Cataldo, CEO and Chairman of GE Biopharma.

Conatus Pharmaceuticals Inc. (CNAT)

This next biotechnology company is known as Conatus Pharmaceuticals Inc. (CNAT). This company’s focus is different compared to GT Biopharma. It aims to treat chronic diseases that have a large unmet need. Its lead product candidate CTS-2090, inhibits IL-1β which treats inflammatory diseases.

biotechnology stocks to watch

In terms of news releases, the company has been slightly lackluster over the last two months. However, in early August Conatus released its Q2 financials which showed some profitability promise in its income statement.

Revenues increased and expenses decreased in Q2 2019 compared to Q2 2018 which significantly reduced the company’s net loss by $3.8 million. One potential hindrance factor in the financials could be Conatus’ consistently declining free cash flow.

Nuvectra Corporation (NVTR)

To top things off, we have a neurostimulation company known as Nuvectra Corporation (NVTR). The company has a commercial product called Algovita Spinal Cord Stimulation which treats chronic pain of the trunk and limbs. In addition to this, Nuvectra is awaiting FDA pre-market approval for its Virtis Sacral Neuromodulation which treats chronic urinary retention and overstive bladders.

breakthrough biotech stocks to watch

Compared to Conatus, Nuvectra has produced recent news that investors can sink their teeth into. First off, the company appointed Jennifer Kosharek as CFO around a month ago. This is a strong appointment thanks to her 15+ years of accounting experience and other leadership positions with Nuvectra.

Furthermore, the company recently submitted its supplementary chemical composition and biocompatibility data to the FDA to support Virtis’ pre-market approval.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, INVESTORS & THE WORLD

biotechnology stocks

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma Inc. (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma Inc. (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma Inc. (GTBP). Full Disclaimer Click Here

Continue Reading

Biotechnology

Are These Biotech Names On Your October Watch List?

Joe Samuel

Published

on

biotech stock price

Over the past two decades, the biotech sector has been one of the best sectors to watch. If experts are to be believed, then it is likely to continue to be a hot sector for the foreseeable future. However, biotech stocks require research and that can help when it comes to making a list of biotech stocks.

Once that is done, the investor needs to track the companies closely. Then it’s easier to decide upon the best course of action. Here is a look at three biotechnology penny stocks this month.

Biotech Stocks To Watch: PharmaCyte Biotech (PMCB)

If you’re looking at PharmaCyte Biotech (PMCB) at this exact moment, you’re seeing it before the company begins clinical trials and just as it’s preparing to complete its Investigational New Drug Application for the FDA.  Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.

best biotechnology stocks to buy now

David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.

“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”

Over the last week, shares of PMCB stock have jumped from $0.0319 to highs of $0.0367 on Friday.

Biotech Stocks To Watch: Hepion Pharmaceuticals (HEPA)                                           

The next biotech stock to watch is Hepion Pharmaceuticals Inc (NASDAQ:HEPA). The company is involved in manufacturing medicines meant for liver conditions emanating from non-alcoholic reasons. The company announced that its research article has been published by the highly influential peer-reviewed journal, the Journal of Pharmacology and Experimental Therapeutics.

The paper in question is titled “A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.” The study shows that Hepion’s product CRV431 could well be a solution for treating chronic diseases of the liver. The paper also stated that the medicine is suited to address a range of therapeutic needs.

Once the news broke, the company’s stock started soaring and soared over 43% at $3.58, well off the session high of $5.59.

Biotech Stocks To Watch: Protalix Biotherapeutics (PLX)

The other biotech stock that broke out more this week is Protalix Biotherapeutics Inc (NYSE:PLX). The company released data from the BRIDGE Phase 3 clinical study of its product PRX-102 and the revelations have proven to be highly encouraging. Out of a total of 22 patients who had been enrolled for the study, the data was gleaned from 16 of them.

The patients in question had been treated with PRX-102 for 12 months. The medicine is meant for treating Fabry disease and it has been revealed that there was an improvement in the function of kidneys in the patients. The stock soared by as much as 75% on Thursday and should definitely be on the watch lists of most investors.

list of healthcare stocks to watch

Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here.

Continue Reading

Biotechnology

Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch

Joe Samuel

Published

on

biotech penny stocks to buy

Biotech & Healthcare ETF’s Made New October Highs; Watching Sector Stocks?

There are certain sectors in the stock market that regularly excite investors. Much of that has to do with the core strength of the sector in question. While tech has been such a sector for more than three decades now, the biotech sector has also been a sector that has helped investors make excellent returns for many years now.

Over the last few trading sessions, both the IBB and XLV ETF’s have taken off to make new October highs. So why wouldn’t healthcare and biotechnology catch someone’s eye?

The biotech sector has a plethora of stocks though. Therefore, an investor needs to put in the necessary research. On that note, here is a look at three biotech stocks to watch as sector stocks enjoy a bull run in October.

GT Biopharma (GTBP) Pops After HIV Data Presentation

GT Biopharma, Inc. (GTBP) is an immuno-oncology company focused on innovative treatments based on the Company’s patent-pending TriKE™ technology. It’s also a biotech stock that has been on the move this month. Earlier in October the company announced key presentation data on its HIV TriKE™ platform.

GT Biopharma (GTBP) Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

Tim Schacker , M.D., Jeffrey S. Miller , M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg.

biotechnology stocks to watch

Research findings from Dr. Schacker’s and Dr. Miller’s laboratories show enhanced NK cell cytokine production and killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE™. This could be a big step for the company and one that has caught some attention this month.

In comparison, the use of anti-retroviral drugs have substantially improved the health and increased the longevity of individuals infected with the human immunodeficiency virus (HIV). But these drugs are designed to suppress virus replication to help modulate progression to AIDS and to limit further transmission of the virus. In this case, GTBP’s HIV-TriKE™ was actually able to kill HIV in the reservoir.

Achillion Pharmaceuticals (ACHN) Jumps On Buyout

One of the biotech stocks that made a remarkable move this week was Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) after it was announced that the company was going to be acquired by Alexion Pharmaceuticals. According to the announcement, Achillion is going to be acquired in a deal worth $930 million.

 It is a deal that is going to be completed entirely in cash. Alexion is paying a premium of 73% above the closing price of the Achillion stock on Tuesday. That works out to a price of $6.30 a share and on Tuesday, the stock had closed at $3.65 a share.

The announcement lit a fire on the Achillion stock and it zoomed by as much as 75% on Wednesday. Considering the sort of premium that is being paid, it is not really a surprise for most market watchers to take notice.

Atossa Genetics (ATOS) Gains On Phase 2 clinical study

The other biotech stock that is in the news today is that of Atossa Genetics Inc (NASDAQ:ATOS). The clinical-stage biopharmaceutical company that is engaged in developing treatments for breast cancer, made a major announcement.

[REPORT] BIOTECH INVESTORS TURN ATTENTION TO TARGETED TREATMENT; ONE COMPANY STANDS OUT

It has been announced that its microcatheter technology has been approved for a Phase 2 clinical study by the Institutional Review Board (IRB).

The technology helps in administering fulvestrant in breast cancer patients and could have major implications for the company’s long term growth. The market believed so as well and the Atossa stock climbed as much as 4.50% after the news broke on Wednesday.

biotechnology stocks to buy now

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com